APA (7th ed.) Citation

N, Z., C, T., V, D. B., W, W., GG, R., TD, H., & I, L. (2025). CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors. Frontiers in oncology, 15, 1626301. https://doi.org/10.3389/fonc.2025.1626301

Chicago Style (17th ed.) Citation

N, Zouggari, Trugenberger C, Du Bois V, Wang W, Rossetti GG, Halazonetis TD, and Labidi-Galy I. "CldU Sensitizes BRCA2 Reverse-mutated Cells to PARP Inhibitors." Frontiers in Oncology 15 (2025): 1626301. https://doi.org/10.3389/fonc.2025.1626301.

MLA (9th ed.) Citation

N, Zouggari, et al. "CldU Sensitizes BRCA2 Reverse-mutated Cells to PARP Inhibitors." Frontiers in Oncology, vol. 15, 2025, p. 1626301, https://doi.org/10.3389/fonc.2025.1626301.